Tecentriq (Atezolizumab): What It Is and What to Expect

Tecentriq is the brand name. Atezolizumab is the generic name. It is a lab-made antibody that blocks PD-L1. PD-L1 is a protein carried by some tumor cells and by immune cells around them. It works like an off switch for T cells. Blocking it can let those T cells see the cancer again.

For two lung cancer uses, a lab test decides. After surgery for stage II to IIIA lung cancer, the label asks for PD-L1 on at least 1% of tumor cells. For first-line metastatic lung cancer given on its own, the bar is much higher. Both readings must come from an FDA-authorized test. Ask which test was run on your tumor sample, and what it showed.

The FDA label lists six cancers.

• Non-small cell lung cancer, in five separate settings.
• Extensive-stage small cell lung cancer, with carboplatin and etoposide; later, with lurbinectedin as maintenance.
• Liver cancer, paired with bevacizumab, when no drug treatment has been given before.
• Melanoma with a BRAF V600 change, together with cobimetinib and vemurafenib.
• Alveolar soft part sarcoma, a rare soft-tissue cancer, from age 2 upward.
• Bladder cancer, but only after the bladder has been removed, and only when a blood test still finds tumor DNA.

Two older bladder cancer approvals were pulled and no longer appear on the label. If you find them described online, check the date on the page.

The drug goes into a vein through a drip. Your team may use a 2-week, 3-week or 4-week cycle, and the dose changes to match the gap. The first drip runs over about an hour. If you handle it well, later ones can be shorter. A separate product, Tecentriq Hybreza, is injected under the skin instead. It has its own label and its own dosing.

The effects people report most often are tiredness, low appetite, feeling sick, rash and breathlessness.

The label's main safety message is a different one. Taking a brake off the immune system can let it attack healthy tissue. The label calls these immune-mediated reactions. It says they can be severe, and that some have been fatal. They have shown up in the lungs, bowel, liver, skin, hormone glands, kidneys, nerves, eyes, heart and muscle. They can begin weeks or months into treatment. Some begin after the last dose.

• Call 911 or go to an emergency department if you struggle to breathe or get chest pain, if a rash starts to blister or peel, or if you have a seizure, sudden weakness, or a bad headache with a stiff neck. Immune-mediated reactions in the lungs, skin, nerves and heart can turn severe quickly.
• Call your care team the same day if your stools turn loose far more often than usual or carry blood, your eyes or skin look yellow, your urine turns dark, or you pass much less urine than normal. A temperature of 100.4°F (38°C) or higher also counts — and if you are having chemotherapy alongside this drug, treat that fever as an emergency instead: CDC says to call your doctor immediately, so ring the team at any hour, and head to an emergency department only if you cannot reach them quickly.
• Call your care team within a day or two if you feel unusually cold, drained or thirsty for no clear reason, or sores appear in your mouth. Hormone glands are a common late target, and the change can be slow enough to miss.

Steroids often settle these reactions when they are caught early. Waiting makes them harder to treat. Tell any clinician who treats you that you have had a checkpoint inhibitor, even months later.

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee

https://www.cancer.gov/about-cancer/treatment/drugs/atezolizumab

https://www.cdc.gov/cancer-preventing-infections/patients/fever.html